Canada markets closed

Affimed N.V. (AFMD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.0900+0.0500 (+2.45%)
At close: 04:00PM EST
2.0501 -0.04 (-1.91%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close2.0400
Open2.0400
Bid2.0600 x 27000
Ask2.0800 x 2900
Day's Range1.9800 - 2.0950
52 Week Range1.4000 - 6.9100
Volume2,196,883
Avg. Volume1,700,519
Market Cap312.119M
Beta (5Y Monthly)2.17
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Motley Fool

    Why Shares of Affimed Fell Thursday

    Shares of German immuno-oncology company Affimed Therapeutics (NASDAQ: AFMD) were down a little more than 15% on Thursday afternoon. There was no big news from the biotech company, but clinical-stage biotechs are considered riskier stocks than most, and with the markets dropping in general on Thursday, Affimed's shares took a hit. Investors are waiting to hear next month how two clinical trials are faring for one of the company's lead therapies in AFM13.

  • Simply Wall St.

    Affimed Third Quarter 2022 Earnings: Beats Expectations

    Affimed ( NASDAQ:AFMD ) Third Quarter 2022 Results Key Financial Results Revenue: €15.0m (up 69% from 3Q 2021). Net...

  • Zacks

    Affimed N.V. (AFMD) Reports Q3 Loss, Tops Revenue Estimates

    Affimed N.V. (AFMD) delivered earnings and revenue surprises of 42.11% and 96.03%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?